The global autoimmune disease diagnostics market is expected to witness steady growth during forecast period. This is primarily due to steady rise of autoimmune diseases, increasing patient pool, and intensification of patient understanding regarding early detection and treatment. In view of this, various recent developments regarding scientific advancements have further boosted this market. Hence, this market is expected to register steady growth to reach US$3.71 Billion in 2025 from US$ 5.86 Billion during 2034 at a Compound Annual Growth Rate (CAGR) of 5.22% during 2026-2034.
Autoimmune disease diagnostics are becoming increasingly popular across various nations across the globe. This is because autoimmune disease is increasingly becoming prevalent, and there is increased awareness about early and accurate autoimmune disease diagnostics. In this regard, early autoimmune disease diagnostics are critical to prevent further complications. This is because there have been developments and improvements to laboratory technologies that have improved the accuracy and efficiency of autoimmune disease diagnostics. Moreover, there is improved access to healthcare and increased advocacy and funding towards healthcare diagnostics to improve personalized care. This is because autoimmune disease manifestation comprises various symptoms that overlap, making diagnostics a critical component.
Autoimmune Disease Diagnostics Market Overview
Autoimmune diseases diagnostics comprise a series of medical investigations pertaining to various diagnostic assessments of various autoimmune disorders wherein individuals experience immune-mediated attacks on their own body tissues. Autoimmune diseases include but are not confined to rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, and autoimmune thyroid disorders. The various diagnostic assessments performed on individuals suffering from autoimmune diseases comprise various immune system and blood investigations, including but not confined to antinuclear antibody assays and various enzyme-linked immunosorbent assays. Specific investigations performed on affected individuals comprise a detailed examination of immune system activity.Autoimmune disease diagnostics are becoming increasingly popular across various nations across the globe. This is because autoimmune disease is increasingly becoming prevalent, and there is increased awareness about early and accurate autoimmune disease diagnostics. In this regard, early autoimmune disease diagnostics are critical to prevent further complications. This is because there have been developments and improvements to laboratory technologies that have improved the accuracy and efficiency of autoimmune disease diagnostics. Moreover, there is improved access to healthcare and increased advocacy and funding towards healthcare diagnostics to improve personalized care. This is because autoimmune disease manifestation comprises various symptoms that overlap, making diagnostics a critical component.
Growth Drivers of the Autoimmune Disease Diagnostics Market
Rising Prevalence of Autoimmune Disorders Worldwide
Increased incidence rates for various autoimmune diseases represent a key area for the expansion of the global auto-immune disease diagnostics services market. Autoimmune diseases include rheumatoid arthritis, systematic lupus erythematosus, multiple sclerosis, type 1 diabetes mellitus, auto IMMUNE thyroid diseases, and various others. These diseases show an increased incidence worldwide owing to increased prevalence rates and different environmental factors that contribute to various pro-diseases conditions. Autoimmune diseases possess chronic and progressive disease qualities that necessitate more precise diagnosis to ensure efficient management of these diseases. Therefore, the increased incidence rates for these diseases ensure constant and consequent demand for more efficient auto-immune disease diagnosis services across the world health system. Alas, according to an article that was presented by the National Health Council in September 2024, autoimmune diseases affect 50 million Americans, and women account for 80% of this population, considering that this illness is, in itself, largely complex in diagnosis. Moreover, considering that this issue merely pertains in a statistical manner, autoimmune diseases are reaching epidemic proportions, judging from various examinations done that show a 3%-12% annual growth rate.Advancements in Diagnostic Technologies and Test Accuracy
Technological innovations happening within laboratory diagnostic platforms have been very instrumental in furthering the growth of the autoimmune disease diagnostics market. Today, modernized testing platforms with better sensitivity and specificity have enabled early interventions in various autoimmune disease conditions. With automated testing systems, there has been a reduction in errors. By using advanced testing platforms such as ELISA, chemiluminescence immunoassay, and indirect immunofluorescence assays, there is a better chance of detecting disease-specific autoantibodies. Further, there has been a progression towards providing a platform to personalize disease treatment based on better laboratory values. Hence, growth within the market concerning advanced autoimmune disease diagnostics is also fueled by this. In January 2025, OMNY Health partnered with Scipher Medicine for providing treatment for autoimmune disease. This partnership will involve the integration of the EHR network of OMNY Health and the transcriptomics information received from the PrismRA test.Growing Focus on Early Diagnosis and Preventive Healthcare
Globalized prevention and treatment strategy to ensure preventive healthcare and the detection of diseases at an early stage is another factor responsible for the growing autoimmune disease diagnostic market across the globe. This is because autoimmune disease diagnosis during the initial stage ensures the treatment and cure of diseases on time, making the patients avoid any damage to the affected organs and tissues as well as ensuring an improved lifestyle for patients undergoing treatment. Furthermore, numerous campaigns and programs have been initiated to ensure public awareness about autoimmune diseases and the importance of undergoing diagnosis for autoimmune diseases during the initial stages itself. As understanding and embracing prevention and treatment as an integral part of the healthcare strategy become widespread, the market continues to foresee an upward trend in autoimmune disease diagnosis around the globe. August 2024, Progentec Diagnostics introduces an innovative app to its successful suite of disease diagnosis tools: "CareMGMT" uniquely offers features that are specific to the patient's journey through their illness as they navigate through aspects including, yet not limited to, symptom tracking, and specific information on healthcare as well as news and updates on various studies through various news channels and platforms.Challenges of the Autoimmune Disease Diagnostics Market
Diagnostic Complexity and Overlapping Clinical Symptoms
One of the major challenges in the autoimmune disease diagnostics market is to deal with the complexity associated with accurate disease diagnoses in autoimmune disease patients. Autoimmune disease patients suffer from various diseases that show nonspecific and overlapping symptoms such as fatigue, joint pains, and inflammation in various regions of their bodies. It is also observed that various autoantibodies show cross-reactivity among autoimmune disease patients as well as among healthy patients. Such complexities associated with autoimmune disease patient diagnoses also increase costs associated with disease handling and time taken to diagnose autoimmune disease patients. Autoimmune disease diagnoses require expertise to ascertain disease results; however, improper diagnoses also waste valuable time in providing appropriate disease treatment to autoimmune disease patients.High Cost of Advanced Diagnostic Tests and Limited Access
The cost factor related to sophisticated autoimmune diagnostic methods is another critical factor that is challenging to address. Advances and sophisticated immunopathology, molecular pathologies, and immunopathogenetics require sophisticated equipment and highly qualified personnel, making these technologies cost-prohibitive. In other regions of the globe, especially those that could be classified as poor and middle-income countries, there is limited access to autoimmune disease diagnostic care. The cost factor is thus critical and necessary to address.Autoimmune Disease Diagnostics Equipment Market
The autoimmune disease diagnostics equipment market is largely influenced and promoted by the increasing demand for accurate and innovative diagnostic solutions. Diagnostic equipment such as immunological analyzer systems, ELISA reader systems, fluorescence microscopes, chemiluminescence analyzer systems, and others play a critical role in the accurate detection of autoantibodies and inflammation. Since autoimmune diseases require repeat and multiple testing sessions, there is an increasing demand to upgrade these services with highly innovative and accurate autoimmune disease diagnostics equipment. Research and developments have improved these machines with technologically advanced solutions such as digital imaging and accurate data management solutions. In recent years, there have been significant and increasing investments in laboratory infrastructure, especially within emerging nations. Since early and accurate detection is becoming increasingly crucial within such regions and nations, there is a growing demand for highly innovative and accurate autoimmune disease diagnostic equipment.Autoimmune Disease Diagnostics Systemic Market
The systemic autoimmune disease diagnostics market deals with conditions like systemic lupus erythematosus, systemic sclerosis, and Sjögren’s syndrome. They are characterized as systemic diseases with various organs or systems involved. Differential diagnosis of systemic autoimmune diseases like systemic lupus erythematosus is challenging due to overlapping clinical features and variable clinical progression. Thus, there is an increasing need for diagnostic tests involving the detection of various autoantibodies. Antinuclear antibody tests such as tests for systemic lupus erythematosus and extractable nuclear antigen tests are crucial. There is increasing awareness among patients as well as doctors about the need for prompt diagnosis. Thus, the market is increasing with the increase in the prevalence of systemic autoimmune diseases.Autoimmune Disease Diagnostics Diabetes Market
The autoimmune disease diagnostics of diabetes primarily focuses on the diagnosis of type 1 diabetes and latent autoimmune diabetes in adults. These diseases are a result of immune-mediated destruction of insulin-producing pancreatic beta cells. Diagnosis includes tests that locate autoantibodies against such antigens as GAD, IA-2, insulin autoantibodies, and zinc transporter 8 (ZnT8) antibodies. All these diagnostic approaches hold tremendous potential for early disease diagnosis, considering the importance of timely insulin treatment for proper disease management. Due to rising incidence, especially in children and young adults, the demand for specialized diagnostic tests has also increased. Better screening programs and awareness regarding the differentiation of autoimmune diabetes from type 2 diabetes further contribute to market growth. With a growing focus on personalized diabetes care, autoimmune diabetes diagnostics bear increasing clinical relevance worldwide.Autoimmune Disease Diagnostics Multiple Sclerosis Market
The multiple sclerosis diagnostics segment is primarily influenced by the rising incidence of the disease and the advancement of various neurological diagnostic products. Multiple sclerosis is an autoinflammatory disease that affects the Central Nervous System and has no known cure. The diagnosis of multiple sclerosis has significant consequences in the progression of the disease. Among the aforementioned factors affecting the multiple sclerosis segment, the diagnosis of the disease directly affects the segment. Multiple sclerosis has no known cure for the time being. The disease has qualifying periods for diagnosis. The disease diagnosis involves both autoinflammatory disease diagnosis and the various aspects of the Central Nervous System.The diagnosis has significant implications for the progression of the disease. The disease diagnosis has significant implications for the progression of the disease. The various aspects related to the diagnosis of multiple sclerosis include diagnosis of the autoinflammatory disease and the aspects related to the Central Nervous System. The diagnosis of the autoinflammatory disease is related to the diagnosis of multiple sclerosis. The various aspects related to the diagnosis of multiple sclerosis include diagnosis of the autoinflammatory disease.Autoimmune Disease Diagnostics Hospitals Market
The hospital end-user segment is a major end-user in autoimmune disease diagnostics. The high level of end users in this category can be attributed to various factors associated with their overall capability in providing end-user service in autoimmune disease diagnostics. The use of facilities available to deal with autoimmune disease diagnostics in a hospital setting is high compared to other end users in this market category. The facilities available in hospital settings for providing end-user service in autoimmune disease diagnostics include highly developed laboratories available to deal with autoimmune disease diagnostics in hospital settings and increased investments in hospital infrastructural facilities available to deal with autoimmune disease diagnostics in hospital settings. Additionally, hospital end users are highly important in managing advanced cases of autoimmune disease, which requires constant monitoring in hospital settings.United States Autoimmune Disease Diagnostics Market
The diagnostic market in the United States for autoimmune diseases is one of the most prominent markets worldwide. The market is influenced by factors like the large population affected by autoimmune diseases. Also, the diagnostic tests can be conducted easily with the current healthcare facility. People are increasingly becoming alert towards diseases like autoimmune. The country is-equipped with the most advanced diagnostic cameras. Regulatory support is another factor. There is a large number of hospitals and diagnostic labs. All these factors put together contribute to the growth. Thus, the market is expected to flourish. March 2025: Savara Inc. has announced the commercialization of aPAP ClearPath Dried Blood Spot (DBS) Test in the United States. The diagnostic tests will be able to diagnose Autoimmune Pulmonary Alveolar Proteinosis with a simple finger prick.United Kingdom Autoimmune Disease Diagnostics Market
The market for autoimmune diseases in the UK diagnostic market is drive by a hi-tech public healthcare system. In the UK, the National Health System plays a major role by emphasizing the promotion of diagnostic tests for the prevention of autoimmune diseases by adopting standardized care approaches. Advanced immunoassays are being utilized by diagnostic laboratories for this purpose. Increasing trends in the recognition of autoimmune conditions in both clinicians and patients have resulted in higher rates of testing. Despite the budget limitations in the public sector healthcare system hindering early adoption of many expensive diagnostic technologies, investments in digital pathological analysis and upgrading the infrastructure in labs remain key drivers of this industry. Increasing population demographics with age-related chronic conditions will continue to spur demand in UK autoimmune diagnostics. Jan 2025 - New data was unveiled from P140 by the Preclinical Research team at ImmuPharma to offer an accurate and earlier diagnosis and monitor Systemic Lupus Erythematosus (SLE) and all other autoimmune diseases.India Autoimmune Disease Diagnostics Market
India's autoimmune disease diagnostics market is growing rapidly due to rising disease awareness, increasing prevalence of autoimmune disorders, and the expanding diagnostic infrastructure. With the availability of private diagnostic laboratories and hospital chains, investments are being made to deploy advanced testing technologies, which in turn will enhance access to immunoassays and specialized autoimmune panels. Increase in urbanization and better access to healthcareare propelling higher diagnostic volumes in metropolitan and tier-2 cities. The affordability factor in this price-sensitive market is further aided by cost-effective solutions of testing and local manufacturing within the country. Although some challenges, such as limited awareness in rural areas and reimbursement gaps, remain, government health initiatives and increasing private sector participation are strengthening market growth. As early diagnosis becomes increasingly critical, demand for autoimmune disease diagnostics in India is slated for continued growth. November 2025, Dr. Lal PathLabs launched India's first dedicated laboratory for advanced autoimmune diagnostics for complex autoimmune & inflammatory diseases. The advanced facility expands access to globally benchmarked complement assays for patients in India, with several of these specialized tests being introduced in the domestic market for the first time.Saudi Arabia Autoimmune Disease Diagnostics Market
The Saudi Arabian autoimmune disease diagnostics market is developing steadily, supported by increased healthcare spending and modernization initiatives driven by the government. Access to autoimmune testing continues to be facilitated by investments in advanced hospitals, diagnostic laboratories, and clinics specializing in a variety of disciplines. Awareness among individuals about autoimmune diseases is increasing, while the prevalence of diseases related to lifestyles contributes to the surge in demand for early and accurate diagnosis. The market is dominated by imported diagnostic equipment and test kits, especially in tertiary care. High costs and dependence on imports prevail. The expansion of private health care and diagnostic services supports market growth. Emphasis on improving healthcare quality and outcomes within the national health strategies places Saudi Arabia at an emerging market position for autoimmune disease diagnostics. April 2025 - Fakeeh Care Group has formed a new partnership with Fosun Pharma, a leading innovation-driven healthcare company in the world that focuses on the healthcare industry: pharmaceuticals, medical devices & diagnostics, and healthcare services. The new partnership is part of the ambitious vision of Fakeeh Care Group aiming to enhance healthcare innovation in Saudi Arabia in accordance with the Vision 2030.Market Segmentation
Product
- Therapeutic & Monitoring Equipment
- Diagnostics Equipment
- Drugs
Types
- Systemic
- Localized
Indication
- Rheumatic Disease
- Diabetes
- Multiple Sclerosis
- Inflammatory Bowel Disease
- Others
End-Users
- Hospitals
- Diagnostics Centers
- Others
Country
North America
- United States
- Canada
Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- Netherlands
- Turkey
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Malaysia
- Indonesia
- Australia
- New Zealand
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
All the Key players have been covered from 5 Viewpoints:
- Overview
- Key Persons
- Recent Development & Strategies
- Product Portfolio
- Financial Insights
Company Analysis:
- Abbott Laboratories
- Bio-Rad Laboratories
- Roche Diagnostics
- Siemens Healthineers
- Bio Merieux SA
- Myriad Genetics, Inc.
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific Inc.
Table of Contents
1. Introduction3. Executive Summary
2. Research Methodology
4. Market Dynamics
5. Global Autoimmune Disease Diagnostic Market
6. Market Share
7. By Product
8. By Type
9. By Indication
10. By End Users
11. Countries
12. Porter’s Five Analysis
13. SWOT Analysis
14. Company Analysis
Companies Mentioned
The companies featured in this Autoimmune Disease Diagnostics market report include:- Abbott Laboratories
- Bio-Rad Laboratories
- Roche Diagnostics
- Siemens Healthineers
- Bio Merieux SA
- Myriad Genetics, Inc.
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2026 |
| Forecast Period | 2025 - 2034 |
| Estimated Market Value ( USD | $ 3.71 Billion |
| Forecasted Market Value ( USD | $ 5.86 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
